Loxo Oncology Inc (fka LOXO)

[Zmill]

If I recall correctly, yes.

[FooBarAndGrill]

Zmill, did that in-depth research mention anything about Eli Lilly? Asking for a friend.

[Zmill]

in depth Research on LOXO https://wordpress.com/block-editor/post/msmoneymoves.com/11262

[0whammies]

Cancer drugs - drugs ALONE - $123 BILLION industry. (In case you're wondering why there will never be a ((widely-publicized)) cure).

Cancer industry will always, only "treat" - indefinitely (until death of patient), never find a cure. IMO.

~~~ cancer diagnosis 2016

[crudeoil24]

Congrats, LOXO up $91. in PM w/ merger!

[stocktrademan]

LOXO buy 158.34

bull flag
stochastics oversold while price in the gap up window
macd above 0 bullish with stochastics oversold in lower boundary
price at or below the daily ichimoku cloud while also above the weekly cloud
covered calls can make ~20% per month compounded on margin
so covered call positions make around 7.25x per year even if the stock goes sideways

thinking about it who wouldn't want to get a likely 625% raise every year really without the workplace antics or problems
hmm difficult choice here
























normal chart




log chart

[Phoenix300]

LOXO big move after hours...ASCO presentation

[FooBarAndGrill]

Summary Employee stock option exercises

08/16/2017

Joshua H. Bilenker.. President & CEO.......... 15000 . $1.184
Jacob Van Naarden... Chief Business Officer... 3082 .. $3.648
Jennifer Burstein... Vice President of Finance 1700 .. $11.95

09/15/2017

Joshua H. Bilenker.. President & CEO.......... 15000 . $1.184
Jacob Van Naarden... Chief Business Officer... 3082 .. $3.648
Jennifer Burstein... Vice President of Finance 1700 .. $11.95

[FooBarAndGrill]

The abstract describes the first two patients with RET-fusion lung cancer with and without brain metastases treated with LOXO-292. Both patients had disease progression while receiving prior multi-kinase inhibitors (MKIs). On LOXO-292, both patients achieved partial responses. The first patient was previously treated with RXDX-105, enrolled on the first dose cohort of the Phase 1 trial, received LOXO-292 20 mg daily, and demonstrated a RECIST confirmed partial response. The second patient was previously treated with alectinib (starting at 600 mg twice daily and increased to 900 mg twice daily) and experienced disease progression systemically and in the brain. Due to the rapidly progressive nature of the brain metastases, the patient was ineligible for the Phase 1 trial and received LOXO-292 in doses ranging from 20-100 mg twice daily under an intra-patient dose escalation single patient protocol. The patient demonstrated a RECIST unconfirmed partial response, including a response in the brain, with a confirmatory response assessment pending as of the abstract’s writing. Both patients remained on LOXO-292 as of the abstract’s writing; additional patient follow-up for these two cases will be discussed in the oral presentation. In this early, two patient data set, LOXO-292 has been well-tolerated, with no adverse events attributed to LOXO-292.

“We are excited to present LOXO-292 proof-of-concept clinical data to the clinical community,” said Josh Bilenker, M.D., chief executive officer of Loxo Oncology. “Just four months after initiating a Phase 1 trial, LOXO-292 is already achieving clinically meaningful levels of RET target coverage in patients, as evidenced by anti-tumor activity in pretreated patients. With our Phase 1 trial continuing to dose escalate, we look forward to providing a more comprehensive trial update in 2018.”

[FooBarAndGrill]

Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, announced details of the LOXO-292 abstract that will be presented as a late-breaking oral presentation at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer being held from October 15-18, 2017, in Yokohama, Japan. LOXO-292 is Loxo Oncology’s highly selective RET inhibitor.

[FooBarAndGrill]

Summary of recent 20 Sept. Employee Stock Option Plan (ESOP) Exercised at about $88 to $90.

Shares Name Position
------ ---- --------
15000 Joshua H. Bilenker President & CEO
5000 Avi Z. Naider Director
3082 Jacob Van Naarden Chief Business Officer
1700 Jennifer Burstein Vice President of Finance

[FooBarAndGrill]

Is it time to buy LOXO? Up 20% today.
https://finance.yahoo.com/news/time-buy-loxo-oncology-inc-145527584.html

[FooBarAndGrill]

LOXO phase 1 results.
http://www.investors.com/news/technology/why-this-cancer-biotech-leads-pack-after-hitting-record-high/

[FooBarAndGrill]

Taking this out on a road show.
https://finance.yahoo.com/news/loxo-oncology-announces-initial-loxo-104500931.html

[FooBarAndGrill]

This is the real deal.

[FooBarAndGrill]

Performing well today in a tough mkt

[AugustStockInformer]

Genius stock analyst called this one weeks ago, see his other picks:
https://www.twst.com/news/citigroup-nysec-senior-analyst-explains-new-biotech-ecosystem-liquid-biopsy-cancer-genetics-nasdaqcgix-may-lead-personal-genomic-medicine-loxo-oncology-nasdaqloxo/

May 3, 2017
Yigal Nochomovitz, Ph.D. is a Director and Smid-Cap biotech analyst at Citigroup (NYSE:C) Investment Research & Analysis. In a recent interview with the Wall Street Transcript, Dr. Nochomovitz states that “Loxo has a drug for a rare type of cancer, and so it is going to need to engage with companies that are developing next-generation sequencing tests to do more genetic profiling of tumors.” Specifically, according to Loxo Oncology (NASDAQ:LOXO):

[FooBarAndGrill]

About TRK Fusion Cancer
TRK fusions are chromosomal abnormalities that occur when one of the NTRK genes (NTRK1, NTRK2, NTRK3) becomes abnormally connected to another, unrelated gene (e.g. ETV6, LMNA, TPM3). This abnormality results in uncontrolled TRK signaling that can lead to cancer. TRK fusions occur rarely but broadly in various adult and pediatric solid tumors, including appendiceal cancer, breast cancer, cholangiocarcinoma, colorectal cancer, GIST, infantile fibrosarcoma, lung cancer, mammary analogue secretory carcinoma of the salivary gland, melanoma, pancreatic cancer, thyroid cancer, and various sarcomas. TRK fusions can be identified through various diagnostic tests, including targeted next-generation sequencing (NGS), immunohistochemistry (IHC), polymerase chain reaction (PCR), and fluorescent in situ hybridization (FISH). For more information, please visit www.TRKtesting.com.

[FooBarAndGrill]

About LOXO-195
LOXO-195 is a potent, oral and selective investigational new drug in clinical development for the treatment of patients with cancers that have acquired resistance to initial TRK therapy such as larotrectinib. Growing research suggests that the NTRK genes, which encode for TRKs, can become abnormally fused to other genes, resulting in growth signals that can lead to cancer in many sites of the body. Though drugs such as larotrectinib can induce durable responses in these patients, the cancer may eventually begin to grow again. This phenomenon is called “acquired resistance,” in that the cancer has acquired features conferring resistance to the initial therapy that was once effective. Emerging data in the field of TRK inhibition suggest that acquired resistance may emerge due to TRK kinase point mutations, such as those in the solvent front domain, xDFG domain, or gatekeeper region. LOXO-195 was designed to address these new point mutations and induce a new response in the patient’s cancer. Interested patients and physicians can contact the Loxo Oncology Physician and Patient Clinical Trial Hotline at 1-855-NTRK-123 or email [e-mail].

[FooBarAndGrill]

A formal LOXO-195 IND was recently cleared by the U.S. FDA, and a Phase 1/2 trial is opening globally.

[FooBarAndGrill]

The Cancer Discovery research brief provides early but encouraging evidence that the sequential use of larotrectinib followed by LOXO-195 could extend the total duration of disease control for patients with TRK fusion cancers. An analogous paradigm has already been established for other oncogene-addicted tumors, such as those driven by androgen and estrogen signaling, EGFR mutations and ABL gene fusions. The brief describes the first two patients with TRK fusion cancers who responded to larotrectinib but later relapsed. An adult with colorectal cancer and a child with infantile fibrosarcoma were biopsied at the time of tumor progression and found to have a solvent front TRK mutation in the existing TRK fusion, which explained the diminished activity of larotrectinib. As no other treatment options exist to address TRK fusion solvent front mutations, Loxo Oncology, in collaboration with the U.S. FDA, enabled these patients to access LOXO-195 through emergency use Investigational New Drug applications (INDs). Both patients responded to LOXO-195, with minimal adverse events reported.

[FooBarAndGrill]

LOXO-195 was designed to address anticipated mechanisms of acquired resistance in cancers exposed to a prior TRK inhibitor, including “solvent front” mutations (e.g. NTRK1 G595R, NTRK3 G623R), which are not well-addressed by existing investigational agents. LOXO-195 will be developed as a sequential treatment, to follow larotrectinib or another TRK inhibitor, to extend the total time of benefit from TRK inhibition.

[FooBarAndGrill]

"This publication highlights the potential for LOXO-195 to extend the period of durable disease control for patients with TRK fusion cancers,” said Josh Bilenker, M.D., chief executive officer of Loxo Oncology. “We believe that today’s ASCO presentation establishes larotrectinib as the clear first choice for patients with TRK fusion cancers. However, over time, patients will require new treatment options, since oncogene-addicted metastatic cancers ultimately evade targeted therapies. We have been relentless in the development of LOXO-195 so that it could be ready in time for the current larotrectinib clinical trial participants and future patients who depend upon us to realize the full potential of TRK inhibition in the management of advanced cancer.”

[FooBarAndGrill]

Loxo Oncology Announces Clinical Proof of Concept Publication for Next-Generation TRK Inhibitor LOXO-195

[FooBarAndGrill]

LOXO on CNBC. Exciting news!

[jones99]

Loxo Oncology (LOXO +5.28%) fell over 3% in after-hours trading after it proposed a public offering of common stock, although no amount or size was given.

[jones99]

$LOXO *DJ Loxo Oncology Announces EMA Orphan Drug Designation Granted To LOXO-101 For Treatment Of Soft Tissue Sarcoma

[edge]

Eyeing this oncology stock as my top biotech pick in this space for 2016..............Stay tuned and Shalom.

[agraff04]

"

[stocktrademan]

$LOXO recent news/filings

bullish

## source: finance.yahoo.com

Wed, 10 Jun 2015 20:02:38 GMT ~ LOXO ONCOLOGY, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders


read full: http://biz.yahoo.com/e/150610/loxo8-k.html
*********************************************************

Tue, 09 Jun 2015 14:17:20 GMT ~ Loxo Oncology, Inc. (Nasdaq:LOXO) to Ring the Nasdaq Stock Market Closing Bell

[at noodls] - Jun 9, 2015 ADVISORY, June 09, 2015 (GLOBE NEWSWIRE) -- What: Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on the discovery, development, and commercialization of targeted cancer ...

read full: http://www.noodls.com/view/7B42276437561F06B063589FA17701F1391E179E
*********************************************************

Tue, 09 Jun 2015 14:00:00 GMT ~ Loxo Oncology, Inc. (Nasdaq:LOXO) to Ring the Nasdaq Stock Market Closing Bell

[GlobeNewswire] - Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development, and commercialization of targeted cancer therapies, will visit the Nasdaq MarketSite in Times Square. In honor of ...

read full: http://finance.yahoo.com/news/loxo-oncology-inc-nasdaq-loxo-140000215.html
*********************************************************

Tue, 02 Jun 2015 13:53:01 GMT ~ Can the Rally in Loxo Oncology (LOXO) Shares Continue? - Tale of the Tape


read full: http://finance.yahoo.com/news/rally-loxo-oncology-loxo-shares-135301536.html
*********************************************************

Wed, 27 May 2015 17:04:17 GMT ~ LOXO ONCOLOGY, INC. Financials


read full: http://finance.yahoo.com/q/is?s=loxo
*********************************************************

$LOXO charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$LOXO company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/LOXO/company-info
Ticker: $LOXO
OTC Market Place: Not Available
CIK code: not found
Company name: Loxo Oncology, Inc.
Incorporated In:


$LOXO share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$LOXO extra dd links

Company name: Loxo Oncology, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/LOXO/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/LOXO/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=LOXO+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=LOXO+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=LOXO+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/LOXO/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/LOXO/news - http://finance.yahoo.com/q/h?s=LOXO+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/LOXO/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/LOXO/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/LOXO/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/LOXO/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/LOXO/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/LOXO/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/LOXO/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/LOXO/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=LOXO+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/LOXO
DTCC (dtcc.com): http://search2.dtcc.com/?q=Loxo+Oncology%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Loxo+Oncology%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Loxo+Oncology%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/LOXO/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/LOXO
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/LOXO/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/LOXO/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/LOXO/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/LOXO/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/LOXO/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/LOXO/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/LOXO/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=LOXO&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=LOXO
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/LOXO/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=LOXO+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=LOXO+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=LOXO
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=LOXO
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=LOXO+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/LOXO/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=LOXO+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/LOXO.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=LOXO
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/LOXO/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/LOXO/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/LOXO/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/LOXO/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/LOXO
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/LOXO
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/LOXO:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=LOXO
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=LOXO



$LOXO DD Notes ~ http://www.ddnotesmaker.com/LOXO